ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near London, England, GBR:

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...

Enrolling
Multiple Myeloma
Biological: bb2121
Drug: Talquetamab

Phase 2

Celgene
Celgene

London, United Kingdom and 25 other locations

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

London, United Kingdom and 145 other locations

Patients with relapsed/refractory multiple myeloma will be enrolled in a dose-escalation phase receiving monotherapy CID-103. Once ...

Active, not recruiting
Multiple Myeloma
Drug: CID-103

Phase 1

CASI Pharmaceuticals

London, United Kingdom and 3 other locations

profile of daratumumab when given in combination with Lenalidomide and dexamethasone in participants with relapsed or relapsed and refractory Multiple...

Active, not recruiting
Multiple Myeloma
Drug: Part 1 (Dose Escalation): Daratumumab
Drug: Lenalidomide

Phase 1, Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

London, United Kingdom and 7 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Biological: bb2121
Drug: Dexamethasone

Phase 3

Celgene
Celgene

London, United Kingdom and 59 other locations

Recently updated

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

London, United Kingdom and 211 other locations

doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment o ...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab

Phase 2

Pfizer
Pfizer

London, United Kingdom and 41 other locations

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone ma...

Enrolling
Multiple Myeloma
Drug: ABBV-383

Phase 1

TeneoOne

London, London, City Of, United Kingdom and 29 other locations

phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...

Enrolling
Multiple Myeloma
Drug: Dexamethasone
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

London, United Kingdom and 40 other locations

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose o...

Enrolling
Relapsed/Refractory Multiple Myeloma
Drug: Dexamethasone
Drug: Daratumumab

Phase 1

AbbVie
AbbVie

London, London, City Of, United Kingdom and 22 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems